Here is a complete, exam-focused breakdown of skeletal muscle relaxants from Katzung's Basic and Clinical Pharmacology (16th Ed.).
Skeletal Muscle Relaxants - Pharmacology Exam Notes
Overview: Two Major Groups
| Group | Mechanism | Used For |
|---|
| Neuromuscular Blockers (NMBs) | Act at neuromuscular junction (NMJ) | Surgical paralysis, intubation, ICU |
| Spasmolytics / Antispasmodics | Act in CNS or on muscle calcium | Spasticity, chronic/acute muscle spasm |
PART 1: Neuromuscular Blocking Drugs (NMBDs)
Normal NMJ Physiology (the basis of drug action)
- Action potential → Ca²⁺ influx → ACh released from motor nerve terminal
- ACh binds nicotinic (nAChR) receptors on the end plate → depolarization → muscle contraction
- NMBDs work by interfering with this process
A. Depolarizing Blockers
Only drug: Succinylcholine (Suxamethonium)
| Feature | Detail |
|---|
| Mechanism | Agonist at nAChR - binds and depolarizes end plate, but stays longer than ACh → sustained depolarization → flaccid paralysis |
| Onset | Fastest of all NMBDs (~60 seconds) |
| Duration | Ultra-short (~5-8 minutes) |
| Metabolism | Plasma pseudocholinesterase (not AChE) |
| Phase I block | Depolarizing - all 4 twitches fade equally in TOF, no post-tetanic potentiation |
| Phase II block | With prolonged/repeated dosing - block resembles nondepolarizing (channel desensitization) |
| Uses | Rapid sequence intubation (RSI), status epilepticus |
Adverse Effects of Succinylcholine (HIGH YIELD):
- Hyperkalemia - K⁺ efflux during depolarization; dangerous/fatal in burns, denervation, crush injury, immobility
- Malignant hyperthermia - trigger agent (with volatile anesthetics)
- Bradycardia/arrhythmias - stimulates muscarinic and ganglionic receptors
- Raised intraocular and intragastric pressure
- Postoperative myalgias (from fasciculations)
- Prolonged paralysis in pseudocholinesterase deficiency
Succinylcholine is contraindicated in burns, denervation injuries, hyperkalemia, and personal/family history of malignant hyperthermia.
B. Nondepolarizing Blockers
Mechanism: Competitive antagonists at nAChR - block ACh from binding → no depolarization → flaccid paralysis
Key feature: TOF shows "fade" (4th twitch weaker than 1st) and post-tetanic potentiation - opposite of succinylcholine.
Classification by Duration and Structure:
| Drug | Structure | Duration | Elimination | Key Notes |
|---|
| d-Tubocurarine | Isoquinoline | Long (>50 min) | Kidney 40% | Histamine release, hypotension; historical prototype |
| Atracurium | Isoquinoline | Intermediate (20-35 min) | Hoffman elimination (spontaneous) | Safe in renal/hepatic failure; releases histamine |
| Cisatracurium | Isoquinoline | Intermediate (25-44 min) | Mostly spontaneous | Like atracurium but no histamine release |
| Pancuronium | Steroidal | Long (>35 min) | Kidney 80% | Vagolytic → tachycardia; avoid in renal failure |
| Vecuronium | Steroidal | Intermediate (20-35 min) | Liver (75-90%) | No CV effects; prolonged in liver disease |
| Rocuronium | Steroidal | Intermediate (20-35 min) | Liver (75-90%) | Fastest onset among nondepolarizers; used for RSI when suxamethonium contraindicated |
Memory aid for structure:
- Isoquinolines: aTRACUrium, ciSATRACUrium, TUBOcurarine - "curare" family
- Steroids: PanCURONium, VecURONium, RocURONium - "-ronium" suffix
C. Reversal of Nondepolarizing Block
Cholinesterase inhibitors (indirect reversal):
- Neostigmine, Pyridostigmine - inhibit AChE → more ACh competes at NMJ
- Must combine with atropine or glycopyrrolate to block muscarinic side effects (bradycardia, secretions)
- Edrophonium - faster onset but less effective in deep block
Sugammadex (direct reversal - VERY HIGH YIELD):
- Modified γ-cyclodextrin that encapsulates rocuronium/vecuronium in a 1:1 ratio
- Pulls drug away from NMJ back into plasma
- Reverses even profound block rapidly (2 mg/kg shallow block, 4 mg/kg deep block, 16 mg/kg immediate reversal after rocuronium)
- Does NOT work for succinylcholine or isoquinolines
- Side effect: hypersensitivity/anaphylaxis (rare)
D. Monitoring - Train of Four (TOF)
| Block Type | TOF Pattern |
|---|
| Depolarizing (succinylcholine Phase I) | All 4 twitches equally reduced, no fade |
| Nondepolarizing | Fade (T4 < T1), post-tetanic potentiation |
| Adequate recovery | TOF ratio > 0.9 required for safe extubation |
PART 2: Spasmolytics (Centrally Acting)
Used for chronic spasticity (MS, cerebral palsy, stroke, spinal cord injury).
Baclofen
- Mechanism: GABA-B receptor agonist in spinal cord → reduces excitatory neurotransmitter release from la afferents → decreases motor neuron firing
- Use: Spasticity from MS, spinal cord injury, cerebral palsy
- Route: Oral or intrathecal (for severe refractory spasticity)
- Toxicity: Sedation, muscle weakness
- Withdrawal: Abrupt withdrawal causes rebound spasticity, hallucinations, seizures - taper slowly!
Diazepam (and other benzodiazepines)
- Mechanism: Facilitates GABA-A in spinal cord and brain → increases inhibitory interneuron activity
- Use: Spasticity of almost any origin; acute muscle spasm
- Toxicity: Significant sedation at doses needed for spasm relief
Tizanidine
- Mechanism: α₂-adrenoceptor agonist in spinal cord → pre- and postsynaptic inhibition of reflex motor output
- Use: Spasticity comparable efficacy to diazepam/baclofen
- Toxicity: Drowsiness, hypotension (16-33%), dry mouth, hepatotoxicity - monitor LFTs
- Withdrawal: Rebound hypertension and tachycardia - taper slowly
- Drug interaction: CYP1A2 inhibitors increase plasma levels
PART 3: Dantrolene (Peripheral Acting)
Unique - acts directly on skeletal muscle, not CNS.
| Feature | Detail |
|---|
| Mechanism | Binds RyR1 (ryanodine receptor) on sarcoplasmic reticulum → blocks Ca²⁺ release → reduces muscle contraction |
| Selectivity | Affects fast-twitch > slow-twitch; cardiac/smooth muscle spared (use RyR2, not RyR1) |
| Primary use | Malignant hyperthermia (IV, 1 mg/kg, repeat up to 10 mg/kg) |
| Secondary use | Chronic spasticity (MS, cerebral palsy) |
| Toxicities | Generalized muscle weakness, sedation, hepatotoxicity (potentially fatal - monitor LFTs) |
| Oral dose | Start 25 mg/day, up to 100 mg QID |
Malignant Hyperthermia (MH) - High Yield:
- Triggered by volatile anesthetics (halothane, sevoflurane) + succinylcholine
- Caused by RyR1 mutation → uncontrolled Ca²⁺ release → massive muscle contraction
- Signs: rising end-tidal CO₂ (earliest sign), hyperthermia, rigidity, acidosis, rhabdomyolysis
- Treatment: Stop trigger, 100% O₂, IV dantrolene, cooling, correct acidosis
PART 4: Antispasmodics (for Acute Local Muscle Spasm)
These are for acute spasm from local injury/strain (not true spasticity):
| Drug | Notes |
|---|
| Cyclobenzaprine | Prototype; tricyclic-like structure; antimuscarinic side effects; sedation |
| Carisoprodol | Schedule IV; metabolized to meprobamate; abuse potential |
| Methocarbamol | CNS depressant; less studied |
| Chlorzoxazone | Hepatotoxicity risk |
All act primarily at brainstem level. Not effective for spasticity from CNS lesions.
Quick Comparison Summary
| Drug | Site of Action | Mechanism | Key Use |
|---|
| Succinylcholine | NMJ | Depolarizing agonist | RSI |
| Rocuronium/Vecuronium | NMJ | Competitive antagonist | Surgical relaxation |
| Sugammadex | Plasma | Chelates rocuronium | Reversal |
| Neostigmine | NMJ | AChE inhibitor | Reversal of nondepolarizing |
| Baclofen | Spinal cord | GABA-B agonist | Spasticity (MS, SCI) |
| Tizanidine | Spinal cord | α₂ agonist | Spasticity |
| Diazepam | CNS/spinal | GABA-A facilitator | Spasticity/acute spasm |
| Dantrolene | Muscle SR | RyR1 blocker | Malignant hyperthermia |
| Cyclobenzaprine | Brainstem | Unknown (antimuscarinic) | Acute local spasm |
(Source: Katzung's Basic and Clinical Pharmacology, 16th Ed., Chapter 27)